Style | Citing Format |
---|---|
MLA | Azizmohammadi S, et al.. "High-Level Expression of Ripk4 and Ezh2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer." Oncology Research, vol. 25, no. 4, 2017, pp. 495-501. |
APA | Azizmohammadi S, Azizmohammadi S, Safari A, Kaghazian M, Sadrkhanlo M, Behnod V, Seifoleslami M (2017). High-Level Expression of Ripk4 and Ezh2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer. Oncology Research, 25(4), 495-501. |
Chicago | Azizmohammadi S, Azizmohammadi S, Safari A, Kaghazian M, Sadrkhanlo M, Behnod V, Seifoleslami M. "High-Level Expression of Ripk4 and Ezh2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer." Oncology Research 25, no. 4 (2017): 495-501. |
Harvard | Azizmohammadi S et al. (2017) 'High-Level Expression of Ripk4 and Ezh2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer', Oncology Research, 25(4), pp. 495-501. |
Vancouver | Azizmohammadi S, Azizmohammadi S, Safari A, Kaghazian M, Sadrkhanlo M, Behnod V, et al.. High-Level Expression of Ripk4 and Ezh2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer. Oncology Research. 2017;25(4):495-501. |
BibTex | @article{ author = {Azizmohammadi S and Azizmohammadi S and Safari A and Kaghazian M and Sadrkhanlo M and Behnod V and Seifoleslami M}, title = {High-Level Expression of Ripk4 and Ezh2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer}, journal = {Oncology Research}, volume = {25}, number = {4}, pages = {495-501}, year = {2017} } |
RIS | TY - JOUR AU - Azizmohammadi S AU - Azizmohammadi S AU - Safari A AU - Kaghazian M AU - Sadrkhanlo M AU - Behnod V AU - Seifoleslami M TI - High-Level Expression of Ripk4 and Ezh2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer JO - Oncology Research VL - 25 IS - 4 SP - 495 EP - 501 PY - 2017 ER - |